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The glutathione transferases (GSTs) are one of the most important families of 
detoxifying enzymes in nature. The classic activity of the GSTs is conjugation of 
compounds with electrophilic centers to the tripeptide glutathione (GSH), but many 
other activities are now associated with GSTs, including steroid and leukotriene 
biosynthesis, peroxide degradation, double-bond cis-trans isomerization, 
dehydroascorbate reduction, Michael addition, and non-catalytic “ligandin” activity 
(ligand binding and transport). Since the first GST structure was determined in 1991, 
there has been an explosion in structural data across GSTs of all three families: the 
cytosolic GSTs, the mitochondrial GSTs and the membrane-associated proteins in 
eicosanoid and glutathione metabolism (MAPEG family). In this review, the major 
insights into GST structure and function will be discussed. 
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Introduction 
Detoxification is a vital metabolic and defense capability of living organisms. The 
glutathione transferases (formerly glutathione S-transferases, GSTs) play a significant 
role in detoxification across multiple kingdoms and phyla. The key reaction catalyzed 
by this superfamily is conjugation of the tri-peptide glutathione (GSH, γ-glutamyl-
cysteinyl-glycine) with a hydrophobic co-substrate possessing an electrophilic center 
(E.C. 2.5.1.18), although many related activities are known. Conjugation with GSH 
renders those compounds more soluble and substrates for cellular export proteins such 
as the multidrug resistance related protein (MRP1) which are ATP binding cassette 
(ABC) transporters (Suzuki et al. 2001). Three distinct superfamilies of GST are 
recognized: the cytosolic GSTs (which form the largest superfamily), the 
mitochontrial and the microsomal GSTs. The microsomal GSTs are integral 
membrane proteins, now designated as membrane-associated proteins in eicosanoid 
and glutathione metabolism (MAPEGs). Several GSTs utilize GSH not as substrates 
but as cofactors (in e.g. leukotriene biosynthesis). The roles of GSTs are many. Apart 
from GSH-conjugation, GSTs function in hormone biosynthesis, tyrosine degradation, 
peroxide breakdown, dehydroascorbate reduction and other functions (Hayes et al. 
2005). Perhaps most surprising is the action of GSTP1 in the inhibition of c-Jun N-
terminal kinase (JNK) signaling activity (Adler et al. 1999).  
 
Protein sequence and structure form a basis for classification of GSTs. Among 
cytosolic GSTs, members of the same class possess greater than 40% amino acid 
sequence identity. Between classes, proteins have less than 25% sequence identity. 
The currently recognized classes of cytosolic GSTs (with references to representative 
structures) are alpha (Sinning et al. 1993), beta (Rossjohn et al. 1998b), delta (Wilce 
et al. 1995; Oakley et al. 2001), epsilon (Sawicki et al. 2003), zeta (Polekhina et al. 
2001), theta (Rossjohn et al. 1998a), mu (Ji et al. 1993), nu (Schuller et al. 2005), pi 
(Reinemer et al. 1992), sigma (Ji et al. 1995; Kanaoka et al. 1997), tau (Thom et al. 
2002), phi (Reinemer et al. 1996) and omega (Board et al. 2000). The mitochondrial 
GSTs share a deep evolutionary relationship with the cytosolic GSTs (discussed 
below) and are designated class kappa. In humans, cytosolic GST isozymes in classes 
alpha, zeta, theta mu, pi, sigma and omega are found. Both cytosolic GSTs and 
mitochondrial GST form dimers; heterodimers of cytosolic GSTs have been identified 
containing chains belonging to the same class. The MAPEG family consists of four 
subgroups (I–IV). Between subgroups, protein sequences share less than 20% 
sequence identity. In humans, six MAPEG isozymes have been identified that belong 
to subgroups I, II, and IV (Jakobsson et al. 1999a). Like the cytosolic- and 
mitochondrial GSTs, several MAPEGs such as MGST1 catalyse conjugation of GSH 
to a number of electrophilic compounds. Other members additionally catalyze 
reactions in leukotriene and protstaglandin biosynthesis (Hayes et al. 2005). 
 
Several GSTs are of pharmacological interest. In humans, most classes of cytosolic 
GST catalyze conjugation reactions with drugs and other xenobiotics (Hayes et al. 
2005). Isozymes of class alpha and zeta are known to possess GSH-dependant 
isomerization activities and will be discussed below. The sigma-class GST known as 
hematopoeitic prostaglandin D syntase catalyses PGD2 formation from PGH2 in a 
GSH-dependant manner. Certain of the theta-class GST isozymes possess sulfatase 
activity (Rossjohn et al. 1998a). The omega-class GSTs share common features with 
the glutaredoxins: they form mixed-disulfides with GSH and catalyse reductase 
reactions (Board et al. 2000). In bacteria, the beta-class GSTs are implicated in a 
variety of distinct processes such as protection against chemical and oxidative 
stresses, antimicrobial drug resistance and in the catabolism of xenobiotics (Allocati 
et al. 2009). 
 
Several non-GST proteins have been shown known to contain the topological and 
ligand-binding features of cytosolic GSTs. These include the intracellular chloride ion 
channels (CLICs) (Harrop et al. 2001; Cromer et al. 2007; Littler et al. 2010), 
microsomal prostaglandin E synthase type-2 (mPGES-2) (Yamada et al. 2005), yeast 
elongation factor 1Bγ (Jeppesen et al. 2003), and the yeast prion protein Ure2p (a 
nitrogen catabolite repression regulator) (Bousset et al. 2001). It is noteworthy that 
Ure2p shows glutathione-dependent peroxidase (GPx) activity, (a frequent adjunct 
activity of GSTs), but no GST activity toward the classic GST substrate 1-chloro-2,4-
dinitrobenzene (CDNB). The GSH conjugating activity of Ure2p can be restored by 
site-directed mutagenesis (Zhang et al. 2008). The structure of Stringent starvation 
protein A (sspA), an RNA-polymerase-associated protein, represents a distinct class 
of bacterial GST-like proteins (Hansen et al. 2005). SspA lacks GST activity and does 
not bind glutathione.  
 
General structural features of GSTs 
cytosolic GSTs and mitochondrial GSTs 
Because of their relevance to toxicology, cancer and drug metabolism (see reviews in 
this issue), the mammalian cytosolic GSTs (in particular, the alpha-, mu- and pi-class 
isozymes) were among the first to be structurally characterized. The first structure 
determined for any GST was of the porcine pi-class enzyme (pGSTP1-1) (Reinemer 
et al. 1991) This isozyme contains the indicative features of members of the cytosolic 
GST superfamily and serves as a point of comparison with other isozymes: an N-
terminal thioredoxin-like domain (with βαβαββα topology) and a C-terminal domain 
composed of α-helixes (Figure 1a). The determination of the structure of rat 
(rGSTK1-1) (Ladner et al. 2004) and human (hGSTK1-1) (Li et al. 2005) 
mitochondrial GSTs revealed striking topological similarities and differences with 
respect to the cytosolic GSTs. The kappa-class enzymes have a thioredoxin-like 
domain, but with a DsbA-like α-helical domain inserted between helix- α2 and 
strand-β3 (Figure 1b). The mPGES-2 protein represents a special case: the structure 
contains the topological features of the cytosolic GSTs but with additional structural 
elements (Yamada et al. 2005) (Figure 1c). In cytosolic GSTs, cytosolic GST-like 
proteins and mitochondrial GSTs, the binding-site for GSH (the “G-site”) is formed 
by the thioredoxin-like domain. A fundamentally conserved interaction found in all 
classes of cytosolic GSTs and in mitochondrial GSTs is a cis-proline residue (found at 
the N-terminal end of strand β3) that forms hydrogen-bond interactions with the 
backbone amine group of the GSH-cysteinyl moiety. The region containing helix α2 
shows the greatest variability among the various classes. This secondary structure 
element contains residues that interact with the glycine-residue of GSH. Global 
analysis of sequence and structural similarity of the cytosolic GSTs reveal two major 
subgroups (Atkinson and Babbitt 2009). These subgroups can be classified as Y-
GSTs, which utilize a tyrosine residue to activate glutathione, and the S/C-GSTs that 
utilize serine (or in the beta- and omega-class GST, cysteine) in their interaction with 
GSH. In both the Y- and S/C-GSTs (and mitochondrial GSTs), the catalytic GSH-
activating residue occurs in a “catalytic loop” following the first β-strand in the 
thioredoxin-like domain. In humans, the Y-GSTs include alpha, mu, pi, sigma-class 
isozymes, with all other classes of GST falling into the S/C-GST subfamily. Where a 
catalytic tyrosine or serine is present, the hydroxyl groups’ of these residues donate a 
hydrogen bond to the GSH sulfhydryl, promoting the formation of thiolate anion. The 
importance of this hydroxyl group has been demonstrated in several mutagenesis 
studies. For example, the hGSTP1-1 Y7F mutant shows severely attenuated activity 
(Kong et al. 1992a) and that the Y7 hydroxyl group acts to lower the pKa of GSH 
sulfhydryl group by 2.4 pH units (Kong et al. 1992b). Similar studies have confirmed 
the importance of serine in S/C-type GSTs [e.g. in human theta-class (Tan et al. 
1996)], although the function of catalytic-loop cysteine residue in beta-class GSTs is 
not as clear (Allocati et al. 2000). The kappa-class isozymes resemble the theta-class 
GSTs in that they utilize a GSH-activating serine residue. The omega-class GSTs 
utilize a catalytic cysteine residue and, like the beta-class isozymes, can form a mixed 
disulfide with GSH. They are thus able to catalyze reductive reactions (Board et al. 
2000). In this way the omega-class GSTs are similar to the glutaredoxins which also 
form mixed disulfides with GSH. The intriguing CLICs have retained the ability to 
bind GSH and, like glutaredoxins beta- and omega-class GSTs, can form mixed 
disulfides with it. To date, no GST-related activities have been detected in CLICs. 
The location of the binding site for hydrophobic co-substrates (the “H-site”) was first 
revealed in the crystal structure of the human pi-class GST, hGSTP1-1 (Reinemer et 
al. 1992), which was co-crystallized with S-hexyl glutatione. It is adjacent to the G-
site and in the cytosolic GSTs is formed in a cleft between the N- and C-terminal 
domains, both of which may contribute residues to its formation. The H-site varies 
greatly in shape and chemical character between classes. Several examples are 
described below.  
 
MAPEG 
Recent significant achievements in the understanding of MAPEG protein structure are 
the determination of MGST1 from rat at 3.2/4.0 Å resolution by electron 
crystallography (Holm et al. 2006), the X-ray crystal structures of human LTC4 
synthase (LTC4-S) in its apo and GSH-complexed forms at 2.00 and 2.15 Å (Martinez 
Molina et al. 2007) and 3.3 Å resolution (Ago et al. 2007) (Figure 2). Of clinical 
relevance was the structure of 5-lipoxygenase-activating protein (FLAP) with MK-
591 and an iodinated derivative at 4.25 and 4.0 Å resolution (Ferguson et al. 2007). 
MK-591 is an inhibitor of leukotriene B4, C4, D4 and E4 synthesis and is in trials for 
the treatment of asthma. All of these are unrelated to the cytosolic- and mitochondrial 
GSTs, and belong to subgroup-I of the MAPEG family. All the MAPEG proteins are 
left handed four-a-helix bundles (TM1 to TM4) (Figure 1d) assembled into trimers, 
with the helical bundles oriented orthogonally in the plane of the membrane (Figure 
1d, 2a). The overall topology of MGST1 and LTC4-S is strikingly similar to subunit I 
of ba3-cytochrome c oxidase. There are three GSH-binding sites per trimer, located 
proximal to the cytoplasmic side of the predicted membrane-spanning regions. The 
MGST1 structure suggested that GSH was bound in an extended conformation, 
similar to that found in the c- and mitochondrial GSTs, however in the higher 
resolution LTC4-S structures, it is in a V-shaped conformation with its thiol group 
oriented toward the membrane where it can presumably interact with its membrane-
bound substrate. The binding site itself appeared to be formed between two monomers 
and the cytoplasmic extension of helix-TM2 contributes the most residues (Figure 
2c). The key GSH-binding residues in LTC4-S are R51, N55, E58, Y59, Y93, Y97 
and R104 and from the adjacent monomer, R30 and Q53. Residue R104 appears to 
play a key role in GSH-activation: the positive charge on the guanadinium group, and 
its direct interaction with the GSH-thiolate would be expected to promote the pKa 
shift necessary for deprotonation (Figure 2c). The structures of FLAP with MK-591 
and homolog show that the inhibitors bind in pocket adjacent to the GSH-binding site 
and inside the membrane-spanning regions. 
 
GSTs in detoxification 
Because of their role in detoxification, both human and pathogen GSTs have been the 
subject of considerable study. For example, polyaromatic hydrocarbons (PAHs, an 
important class of environmental pollutant) oxidized by CYP450s are substrates for 
multiple classes of GST. Another example from oncology concerns human tumors 
that express raised levels of pi-class GST. hGSTP1 expression is correlated with 
resistance to chemotherapeutics such as chlorambucil, cyclophosphamide, BCNU 
(N,N’-bis(2-chloroethyl)-N-nitrosourea), and cisplatin (Laborde 2010). The structures 
of several GSTs and their interactions with substrates and inhibitors have been 
determined. 
 
Early efforts to determine the structures of GSTs focused on inhibitors used to 
enhance the efficacy of chemotheraputic agents that they detoxify. Ethacrynic acid, 
[2,3-dichloro-4-(2-methylenebutyryl)phenoxy]acetic acid (EA), is a well-
characterized inhibitor of alph-, mu- and pi-class GSTs. Originally used as a diuretic, 
EAis probably the most extensively studied GST inhibitors, and was used in clinical 
trial with chlorambucil for the treatment of drug-resistant chronic lymphocytic 
leukemia (Tew 1994). EA is both an inhibitor and substrate of hGSTP1-1 (Figure 3a). 
The crystal structures of both hGSTA1-1 (Cameron et al. 1995) and hGSTP1-1 
(Oakley et al. 1997c) in complex with the diuretic drug EA and its GSH-conjugate 
(GS-EA) have been determined (Figure 3b, c, d ,e). These studies were among the 
first to demonstrate that the H-sites of the pi- and alpha-class GSTs bind similar 
compounds distinctly. The alpha-class isozyme has an additional α-helix (α9) at its 
C-terminus that occludes the H-site (Figure 3d, e). When hGSTA1-1 binds EA, both 
the H- and G-sites are at least partially occupied, blocking entry of GSH (Figure 3). 
However, in the hGSTP1-1 complex, EA is bound entirely in the H-site, albeit in a 
manner not productive for conjugation with GSH. The structure of hGSTP1-1 with 
bound GS-EA demonstrated that rearrangement of the substrate in the active site was 
essential for catalysis in that isozyme. The structure also indicates that the Y108 
hydroxyl (in the H-site) participates in conjugation through the donation of a 
hydrogen-bond to the ketone moiety of EA, stabilizing the Michael addition reaction 
(LoBello et al. 1997) (Figure 3c). The structure of hGSTA1-1 in complex with GS-
EA shows that the EA-moiety is partially disordered, with two orientations can be 
observed. Curiously, a second orientation of the EA-moiety in the hGSTP1-1 GS-EA 
complex was observed (Oakley et al. 1997a). Taken together, the results suggested 
that GSTs have considerable versatility in the binding of ligands in the H-site. 
 
The metabolism of PAHs represent an important detoxification function of GSTs. 
Phenanthrene epoxide (PE), a product of cytochrome P450 oxidation of phenanthrene 
(Figure 4a) can be conjugated to GSH by rat mu-class isozymes rGSTM1-1 and M2-
2. The rGSTM2-2 isozyme is stereospecific in the addition of GSH to the 
phenanthrene epoxide, giving exclusively (9S,10S)-9-(S-glutathiony1)-10-hydroxy-
9,10-dihydrophenanthrene (9S,10S-GSP). In contrast, the rGSTM1-1 subunit is less 
efficient and exhibits little stereoselectivity in this reaction and gives rise to both 
9S,10S-GSP and 9R,10R-GSP diastereoisomers (Boehlert and Armstrong 1984). The 
structure of rGSTM1-1 was determined with both diastereoisomers (Ji et al. 1994) 
(Figure 4b). In the complex with the (9S,10S)-diastereoisomer, the 10’-hydroxyl 
group of the ligand is hydrogen-bonded to Y115-OH suggesting that this residue 
could act as an electrophile to stabilize the transition state for the epoxide ring-
opening reaction.  
 
Benzo[a]pyrene is a PAH whose metabolites are mutagenic and highly carcinogenic. 
The carcinogenic metabolites are stereoisomers of 7,8-dihydroxy-9,10-oxy-7,8,9,10-
tetrahydrobenzo[a]pyrene (BPDE). The (+)-anti-isomer, [(+)-anti-BPDE] is the more 
potent carcinogen (Slaga et al. 1979) (Figure 5a). Allelic variants of hGSTP1 have 
different rates of conjugating activity toward this compound: the activity of 
hGSTP1*B-1*B (containing the I to V substitution at position 104) with (+)-anti-
BPDE is > 3-fold higher than that of the common I104-containing (1*A) isoform. The 
structures of these two isoforms with the conjugation product GS-BPD (Ji et al. 1999) 
(Figure 5a) reveal that residue 104 positions the reaction product (Figure 5b, c) and 
suggest that substrate binding in the hGSTP1*B H-site is more favorable than in the 
hGSTP1*A H-sites. The catalytic advantages afforded by a valine residue at position 
104 are as follows: a favorable Y7-OH to GS-BPD sulfur-atom distance (3.2 Å), a 
hydrogen-bond between R13 guanadinium-NH and the 8’-OH group of the BPD 
moiety, and the positioning of a water molecules in the H-site that mediates a 
hydrogen-bond between Y108-OH and 9’-OH group (Figure 5c). The absence of 
these interactions in the hGSTP1-1 complex suggests that polarization of the BPD-
OH groups assists in attack of GSH thiolate during catalysis. Analogies appear in the 
differences in GSH-conjugating activity of the mouse alpha-class GSTs mitochondrial 
GSTA1-1 and mitochondrial GSTA2-2 toward (+)-anti-BPDE. The GSH-conjugating 
activity of the mitochondrial GSTA1-1 isozyme toward (+)-anti-BPDE is 
approximately 3-fold higher than that of mitochondrial GSTA2-2. The complex of 
GS-BPD with mitochondrial GSTA1-1 (Gu et al. 2000) (Figure 5d) and mitochondrial 
GSTA2-2 (Gu et al. 2003) (Figure 5e) facilitate a structural explanation for these 
differences. Three H-site residues at positions 207, 216 and 221 appear to play a 
critical role. Residue I221 and M207 in allow for positioning of the BPD moiety so 
that the GS-sulfur is 3.25 Å from the Y7-OH group. A guanadinium-NH group of 
residue R216 donates a H-bond to the 8’-OH group in an analogous fashion to R13 in 
the pi-class GST. Finally, the glycyl-NH moiety of GSH donated a H-bond to the 7’-
OH of BPD that may represent substrate assistance in catalysis. In the mitochondrial 
GSTA2-2 complex, the enzyme donates no H-bonds to the hydroxyl oxygen atoms of 
the BPD-moiety and the glutathione sulfur is rotated away from the Y7-OH group 
(distance = 5.2 Å). The positioning of the aromatic ring by F221 and L207 side chains 
do not allow rotation of R216 into the H-site to interact with the BPD-OH groups. 
 
In addition to the conjugation of PAH derivatives, certain of the alpha-class GSTs 
have activity toward products of lipid peroxidation. Structural studies on human 
(Bruns et al. 1999) and murine (Xiao et al. 1999) GSTA4-4 have sought to explain the 
Michael addition activity of that isozyme with lipid peroxidation products such as 4-
hydroxynon-2-enal (HNE). The reaction is intriguing because of the catalytic 
efficiency is high, yet lacks stereoselectivity (Figure 6a). The reaction is complicated 
by the fact the GS-HNE conjugate undergoes reversible cyclization. The cyclized 
form of GS-HNE was observed in a complex with mGSTA4-4 (Xiao et al. 1999) 
(figure 6b). The mechanism remained unclear until recently, when the crystal 
structures of hGSTA4-4 and a chimeric variant of hGSTA1-1 were solved in complex 
with an isosteric analogue of GS-HNE (Balogh et al. 2010), where the aldehyde 
moiety was replaced with an alcohol group (Figure 6c). The structures show that the 
active site residue R15 can interact with the 4’-OH group of either HNE enantiomer 
and assisting catalysis through the polarization of the group through the donation of a 
H-bond. A tyrosine residue peculiar to the A4-4 isozyme, Y212, contributes a 
hydrogen bond to the aldehyde oxygen atom during Michael addition and thus 
stabilizes the enolate reaction intermediate. The absence of this tyrosine residue in 
other alpha-class GSTs explains the enhanced activity of the A4-4 isozyme. The 
catalytic loop-Y9 residue appears to act in the usual manner, activating GSH for 
reaction with the α,β-unsaturated moiety.  
 
The role of GSTs in chemotherapy resistance is of clinical significance. Increased 
levels of pi-class GST have been observed in several tumor cell lines that are resistant 
to a range of anti-cancer drugs, for example, chlorambucil (Tew 1994). The 
anticancer drug chlorambucil is a known substrate for hGSTP1-1 and the complex 
with chlorambucil and the chlorambucil-GSH conjugate have been reported (Parker et 
al. 2008). Chlorambucil was shown to bind in the H-site and substrate must undergo 
re-arrangement in the active site for conjugation with GSH to occur. This 
phenomenon was observed with EA as noted above. With the aforementioned role of 
hGSTP1-1 in chemotherapy resistance, efforts to find specific inhibitors were 
undertaken. Evaluation of GST inhibitors with specifically toward hGSTP1-1 over 
other classes lead to the discovery of TLK117 [γ-glutamyl-(S-benzyl)cysteinyl-D-
phenylglycine] (Figure 7a), the most selective hGSTP1-1 inhibitor reported to date 
(Lyttle et al. 1994). The compound has a Ki of 0.4 µM with hGSTP1-1, but over 50-
fold greater with alpha- and mu-class isozymes. The structure of the TLK117-
hGSTP1-1 complex reveals the basis for the selectivity of the compound for pi-class 
isozymes (Oakley et al. 1997b). The D-phenylglycine moiety of the inhibitor contacts 
hydrophobic residues whilst maintaining the multiple hydrogen-bond interactions that 
occur between GSH and the G-site. The substitution of the glycyl moiety in GSH by 
D-phenylglycine in TLK-117 would result in steric clashes in the alpha and mu- class 
enzymes, which maintain intimate contacts with the glycyl residue of GSH (Figure 
7b). In the clinic, TLK117 is administered as a diethyl-ester prodrug, TLK199. While 
the potentiating effects of TLK199 in tumor cells were insufficient to warrant clinical 
trials, TLK199 was shown to act as a small-molecule myeloproliferative agent 
(Laborde 2010). These activities may be due to the disruption of GSTP1-1 with c-Jun 
N-terminal kinase, resulting in the modulation of the kinase pathways that affect cell 
proliferation. 
 
GSTs as ligandins 
Ligandin, originally identified as a cytoplasmic protein that bound various compounds 
including bilirubin, heme, xenobiotics, steroids and azo-dyes was identified with GST 
activity in 1974 (Habig et al.). There is considerable interest in the “ligandin” function 
of GSTs. This activity contributes to intracellular sequestration and transport of 
xenobiotics and hormones. The location of this site appears to vary depending on the 
chemical nature of the ligand and GST-class. Of great interest was the determination 
of the structure of a mu-class GST from Schistosoma japonica with praziquantel 
(McTigue et al. 1995), an anthelmintic effective against flatworms. The drug was 
shown to bind in the dimer interface (Figure 8a, b). This was the first structure in 
which ligand binding outside of the G- and H-sites was demonstrated in a cytosolic 
GST. Several structures of the human pi-class GST feature binding of the buffer-
substances MES or HEPES at a site adjacent to W28, located at the N-terminal end of 
strand β2 (Ji et al. 1997; Oakley et al. 1997b; Prade et al. 1997) (Figure 8c, d). Later 
studies demonstrated binding of ligands in various binding sites: Sulfasalazine (a 
sulfa-drug), cibacron blue (a sulfonated triazine dye) and bromosulfophthalein (used 
in liver function tests) bind in the H-site (Oakley et al. 1999). Binding of ligands in 
the dimer interface is also possible in alpha-class GSTs: affinity labeling of rat 
GSTA3-3 has revealed a ligandin site within the cleft between the two subunits 
(Vargo and Colman 2001). In addition to binding D5-androstene-3,17-dione in the H-
site (see below), rGSTA3-3 binds displays high affinity for 17β-estradiol-3,17-
disulfate. Finally, the structure of a sigma-class GST (from squid) in complex with S-
(3-iodobenzyl)-GSH demonstrates non-substrate binding in the dimer interface in 
addition to the expected mode of binding in the G-and H-site (Ji et al. 1996). Taken 
together the data suggest that observations of ligand-binding interactions in one class 
cannot easily be extrapolated to other classes, or indeed between chemically distinct 
ligands binding to a particular GST isozyme. 
 
GSTs in hormone biosynthesis 
Among the GSTs are enzymes that are involved in the biosynthesis of leukotrienes, 
prostaglandins, and steroid hormones. The mammalian sigma-class GSTs catalyze the 
conversion of PGH2 to PGD2, whereas mPGES’ catalyses the conversion of PGH2 to 
PGE2 (relevant structures are shown in Figure 9). Both utilize GSH as a cofactor in 
their respective reactions. As noted above mPGES-2 contains a cytosolic GST-like 
domain. mPGES-1, however, is a member of MAPEG subgroup IV (Hayes et al. 
2005). Some members of the MAPEG family catalyze the formation of LTC4 and 
PGE2 (Hayes et al. 2005). An alpha-class GST isozyme has been demonstrated to 
catalyze 3-keto-Δ5-steroids to 3-keto-Δ4-steroid isomers (Johansson and Mannervik 
2001). Atomic-resolution structures of some relevant cytosolic GSTs and the non-
membrane-bound fragment of GST-like mPGES-2 are available, and progress has 
been made into the understanding of structures of the integral membrane MAPEG 
enzymes, however there is currently a paucity of structural data on how the hormone 
co-substrates bind, and catalytic mechanisms have been inferred based on modeling. 




The hematopoietic prostaglandin D synthase, (HPDS, a sigma-class GST), catalyses 
the isomerization of PGH2 to PGD2, a mediator of allergy and inflammation. PGH2 is 
an unstable peroxide-containing derivative of arachidonic acid. The structure of the 
rat HPDS (Kanaoka et al. 1997) displayed features in common with the alpha, mu and 
pi class enzymes (such as a GSH-activating tyrosine residue) but had a unique H-site 
structure for binding its largely aliphatic substrate. Divalent cations decrease the Km 
for PGH2 and GSH, increasing PGDS activity. The structure of the human isozyme 
(Inoue et al. 2003) revealed structural details of Ca2+ and Mg2+-mediated activation. 
These ions are bound in the dimer interface via octahedrally coordinated water 
molecules, which are in turn bound to acidic residues clustered around the central 
two-fold axis (Inoue et al. 2003) (Figure 10). One acidic residue, D96 accepts a 
hydrogen-bond from R14, which binds GSH. The role of HPDS in inflammation 
makes it an attractive drug target for inhibition. While no structure of HPDS with a 
substrate or reaction product exists, several enzyme/inhibitor complex structures have 
been determined. A fragment-based screening approach lead to the identification of 
an inhibitor, phenyl-5-(1H-pyrazol-3-yl)-1,3-thiazole with an IC50 of 21 nM, one of 
the most potent inhibitors of HPDS to date (Figure 10c) (Hohwy et al. 2008). A recent 
study demonstrated the binding of nocodazole, an anti-neoplastic agent (IC50 ≈ 65 
mM) (Weber et al. 2010) (Figure 10b, c) 
 
It is worth noting briefly the proposed catalytic mechanism for HPDS: a hydrogen 
bond from the Y8-OH to GSH-thiol was proposed to result in the formation of 
thiolate anion, which engages in nucleophilic attack on the oxygen atom of PGH2. A 
GS- anion in solution then engages in nucleophilic attack on the C11-hydrogen atom 
of the GSH-PGH2 adduct, causing O-S bond cleavage and the formation of the C11 
carbonyl. A hydrogen atom transferred to the C9-hydroxyanion from GSH completes 
the formation of the product (Figure 10d) (Kanaoka et al. 1997). 
 
The mPGES-2 enzyme (Figure 1c) is another target for inhibition due to its PGE2-
forming activity. PGE2 is a regulator of biological activities including smooth muscle 
dilation and contraction (Jakobsson et al. 1999b). The N-terminal domain of mPGES-
2 contains a CPXC active-site motif resembling that found in thioredoxins (Yamada 
et al. 2005). Noteworthy is the fact that mPGES-2 does not require GSH for its 
catalytic activity, although the catalytic rate can be increased from two- to fourfold by 
DTT, dihydrolipoic acid, GSH or other thiol compounds (Tanikawa et al. 2002). The 
structure has been determined in complex with GSH and indomethacin (IMN), a non-
steroidal anti-inflammatory drug and cyclooxygenase inhibitor. Indomethicin is a 
weak inhibitor of mPGES-2 (IC50 ≈ 1mM) (Yamada et al. 2005) (Figure 11a, b). The 
mechanism is unclear but appears to involve the first cysteine of the CPXC motif 
(C110). Although not closely related to HPDS described above, modeling of the 
substrate in mPGES-2 suggested intriguing mechanistic parallels. When mPGES-2 
and HPGDS are superimposed, the C110-SH group of the former overlaps with the 
GSH-thiol of the latter, suggesting that the thiols could perform equivalent functions 
during catalysis. In an update to their previous structural studies on mPGES-2, 
Yamada and Takusagawa (2007) determined the structure of this protein as a complex 
with GSH and heme. Heme lies in the same site as indomethacin (Figure 11c). The 
affinity of mPGES-2 for heme is high (Kd = 0.53 mM) but the physiological role is 
unclear. It was suggested that the GSH-heme complex-bound enzyme catalyzes the 
formation of 12(S)-hydroxy-5(Z),8(E),10(E)-heptadecatrienoic acid (HHT) and 
malondialdehyde from PGH2, however, later biochemical analysis using more 
sensitive assays suggested that HTT production is due to the non-enzyme catalyzed 
reaction of PGH2 with heme (Watanabe et al. 2008). Thus the functional importance 
of heme-binding remains an open question. 
 
Steroids 
Despite having a similar amino acid sequence compared to other human alpha-class 
GSTs, hGSTA3-3 is unique in having high steroid double bond isomerase activity for 
the conversion of Δ5-androstene-3,17-dione to Δ4-androstene-3,17-dione (Gu et al. 
2004). While the structure of this GST has been determined with GSH, the complex 
with a co-substrate has not. However, based on a model of Δ5-androstene-3,17-dione 
in the H-site of hGSTA3-3 (Figure 12a), a mechanism was proposed in which the 
abstraction by GS- of a hydrogen ion from the 4’-carbon of the steroid is followed by 
isomerization and the transfer of a hydrogen ion to the 6’-carbon. The formation of 
thiolate anion is promoted by the active-site tyrosine (Y9). In this scheme, GSH acts 
as a general base rather than substrate. The activity of hGSTA3-3 in this reaction was 
rationalized in terms of two active site residues (G12 and A208) that differ with 
respect to other alpha-class isozymes. The equivalent residues in hGSTA1-1 (A12 and 
M208) would clash with the substrate and prevent binding. The hGSTA3-3 mutants 
G12A and A208M showed significantly attenuated activity (Gu et al. 2004). 
 
A GST in Tyrosine catabolism 
The zeta-class GSTs, also known as maleylacetoacetate isomerase (MAAI) catalyzes 
the isomerization of maleylacetoacetate to fumarylacetoacetate (Figure 13a) with 
GSH as a co-factor, and many other reactions. Its MAAI activity makes it a key 
enzyme in the catabolism of phenylalanine and tyrosine. The other activities of the 
zeta-class GSTs include oxygenation, dehalogenation, peroxidation, and transferase 
activities. Deficiencies in enzymes along the tyrosine degradation pathway lead to 
diseases including phenylketonuria, alkaptonuria, and fatally, hereditary tyrosinemia 
type I. Of clinical interest is the dichloroacetate (DCA) transforming activity of the 
enzyme: DCA is used clinically for the treatment of congenital lactic acidosis, its 
mode of action being the promotion the metabolism of lactic acid via activation of the 
pyruvate dehydrogenase complex (Stacpoole et al. 1998) (see the Anders and Board 
review in this issue). The structure of human MAAI (hGSTZ1-1) was reported at 1.9 
Å resolution in complex with glutathione and a sulfate ion (Polekhina et al. 2001) 
(Figure 13b). While the structure has characteristic features of the cytosolic GST fold, 
it was not clear which if any of the catalytic loop residues function in an analogous 
fashion to the archetypal GSH-activating residues of other classes. Subsequent 
investigation of the catalytic activity of point-mutants toward model substrate 2-
bromo-3-(4-nitrophenyl)propionic acid suggested that of residues S14, S15 and C16, 
only S14 was essential for activity. Based on the increased Km for GSH of the C16A 
mutant, C16 was proposed to position GSH in the active site (Board et al. 2003). This 
observation was somewhat puzzling because S14 does not appear to interact directly 
with GSH (Figure 13a). Further insight into catalysis in this class of GST comes from 
the structure of maleyl pyruvate isomerase (MPI) from Ralstonia sp. U2, a zeta-class 
GST homolog that shares 40% sequence identity with the human isozyme (Marsh et 
al. 2008). Like the human zeta-class enzyme, it is an isomerase utilizing GSH as a 
cofactor. This enzyme functions in the pathway for degradation of naphthalene via 
gentisate that enables the bacterium to utilize polyaromatic hydrocarbons as its sole 
carbon source. The substrate is very similar to that of the human isozyme (Figure 
13a). The structure was determined as a complex with dicarboxyethyl-GSH (an 
analogue of the proposed reaction intermediate) (Figure 13c, d). The structure 
suggests that the GSH thiolate attacks the substrate in the 2’-position, with a 
carboxylate buried at the base of the active site cleft, forming hydrogen bonds with 
H104-Nε2 and crucially, the backbone-NH group of G10 (equivalent to S15 in the 
human isozyme). This interaction helps explain the importance of the preceding 
residue (S14 in the human isozyme) for catalysis despite the orientation of the side-
chain away from the G-site. An arginine residue (R176) was proposed to stabilize the 
formation of enolate oxygen at the 4’-carbon during the Michael addition of GSH 
(Marsh et al. 2008) The arginine residue is highly conserved (R175 in hGSTZ1-1) and 




From a structural perspective, GSTs are the best-characterized enzyme in 
detoxification: structural data covers GSTs of multiple phyla, classes and functions. 
The binding of relevant toxins, drugs, and other ligands to mammalian cytosolic 
GSTs are well characterized. Efforts to uncover the structural secrets of the integral-
membrane MAPEG family of proteins have, in the past five years, yielded fruit. 
Nevertheless, the structural basis for the activity of several classes of GSTs of 
relevance to human health remains mysterious. 
 
Bacterial beta-class GSTs such as that of Proteus mirabilis are proposed to contribute 
to antibiotic resistance through binding of tetracyclines and rifamycin (Perito et al. 
1996). The structure of PmGSTB1-1 has been determined (Rossjohn et al. 1998b), but 
its binding activities are yet to be structurally characterized. Nevertheless, substrate 
binding in one bacterial GST has been described: the structure of BphK from 
Burkholderia xenovorans LB400 in complex with (2Z,4E)-2-hydroxy-6-oxo-6-
phenyl-hexa-2,4-dienoic acid (HOPDA), a product of PCB breakdown, has been 
described (Tocheva et al. 2006). 
 
Further research is needed to characterize substrate binding and catalysis in 
mitochondrial kappa-class GSTs. To date, structures of the rat (Ladner et al. 2004) 
and human (Li et al. 2005) kappa-class GSTs have been determined in the presence of 
glutathione or its analogues but not with a relevant co-substrate. Nevertheless, 
understanding of co-substrate binding in this class has been aided by investigations 
into a bacterial kappa class GST from Pseudomonas putida known as 2-
hydroxychromene-2-carboxylic acid (HCCA) isomerase (Thompson et al. 2007). 
While the sequence identity of HCCA with rGSTK is only 22%, the overall topology 
is highly similar (the RMSD of the superposed structures is 1.9 Å over 180 Cα 
atoms). 
 
The characterization of parasite GSTs will be a fertile area of research in the future, 
and may have potential as targets for inhibition. For example, the malarial parasite 
Plasmodium falciparum possesses one cytosolic GST isoenzyme (PfGST), the 
structure of which was determined (Fritz-Wolf et al. 2003). The sequence and 
structure of PfGST shows that cannot easily be assigned to any extant GST class. The 
activity of PfGST is increased in chloroquine-resistant cells, and has been shown to 
act as a ligandin for parasitotoxic hemin. PfGST represents a promising target for 
antimalarial drug development. In another example, the structure of a novel class of 
GST (nu) from the model hookworm nematode Heligmosomoides polygyrus 
(HpGSTN2-2) has been solved (Schuller et al. 2005). The GST activity of nematodes 
is up-regulated during chronic infection of their hosts. 
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Figure legends 
Figure 1. Topology and structural representations of (a) cytosolic GST (b) 
mitochondrial GST (c) mPGES and (d) MAPEG. The thioredoxin-like domains in (a), 
(b) and (c) are represented in green. The C-terminal domain particular to cytosolic 
GST and mPGES-2 is in cyan (a, c). Additional structural elements of mPGES-2 (c) 
are shown in yellow and magenta. The DsbA-like insertion in mitochondrial GSTs (b) 
is shown in cyan. The approximate location of the membrane around membrane-
spanning portion of MPGES-2 is shown by horizontal bars. In all cartoon 
representations, GSH is represented in stick-form. 
 
Figure 2. Cartoon diagrams of (a) MGST1 (Holm et al. 2006) and (b) LTC4-S 
(Martinez Molina et al. 2007) as viewed from the cytoplasmic face. The monomers in 
each structure are colored red, green and cyan. GSH is shown in stick form. In (c) the 
GSH binding site of LTC4-S is shown. Residues contributed from adjacent monomers 
in green or cyan. The critical GSH-activating R104 is labeled in red. Helices are 
labeled TM1 or TM4. 
 
Figure 3. (a) hGSTP1-1 catalyzed conjugation of EA with GSH. The structures of 
hGSTP1-1 (b, c) and hGSTA1-1 (d, e) are shown as complexes with EA (b, d) and the 
EA-GSH conjugate (c, e). Proteins are represented in cartoon form with ligands and 
key residues drawn in stick form. The domains are colored as for Figure 1a. The 
distinct C-terminal extension of hGSTA1 is colored red. hGSTA1-1 in panel E 
contains the R15K mutation. 
 
Figure 4. (a) Conjugation reaction of PE with GSH. (b) Structures of rGSTM1-1 in 
complex with 9S,10S-GSP (white) or 9R,10R-GSP (yellow). rGSTM1-1 is drawn in 
cartoon form, using the color convention of Figure 1a. 
 
Figure 5. (a) Conjugation of BPDE with GSH. The structures of (b) hGSTP1-1 and 
(c) allelic variant P1*B (I104V) in complex with GS-BPD in cartoon form with key 
residues in stick form. The substituted residue is labeled in red. The complexes of 
BPD-GS with mGSTA1-1 (d) and mGSTA2-2 (e) are illustrated with the reaction 
product and key residues in stick form. In all cases the protein backbone is 
represented in cartoon from, colored according to the convention in Figure 1 and 
Figure 3. 
 
Figure 6. (a) Conjugation of GSH with HNE. (b) structure of mGSTA1-1 in 
complexed with cyclized GS-HNE. (c) Structure of hGSTA1-1 in complex with 
isosteric GS-HNE analog glutathionyl-1,4-dihydroxynonanol. Ligands and critical 
residues are shown in stick form. The protein backbone is represented in cartoon 
from, colored according to the convention in Figure 1 and Figure 3. 
 
Figure 7. (a) Chemical structure of TLK117. (b) hGSTP1-1 (green), hGSTA1-1 (red) 
and hGSTM2-2 (tan) are shown superposed. TLK117 and selected residues are shown 
in stick form. 
 
Figure 8. (a) Cartoon representation of Schistosoma japonica GST dimer with 
praziquantel (b) bound in the dimer interface. (c) Human pi-class GST with MES (d) 
bound. The color convention of figure 1 is used. 
 
Figure 9. Structures of PGH2, PGE2 and PGD2.  
 
Figure 10. (a) Binding of Mg2+ in the dimer interface of HPDS. Residues and water 
molecules linking GSH to Mg2+ are shown in stick form. (b) The active site of HPDS 
with nocodazole (yellow carbon atoms) or phenyl-5-(1H-pyrazol-3-yl)-1,3-thiazole 
(black carbon atoms) bound, and (c) their chemical structures. (d) Proposed 
mechanism of GSH-assisted conversion of PGH2 to PGD2. 
 
Figure 11. (a) Active-site of mPGES-2 (cartoon form) with indomethacin (b) bound. 
(c) Active-site of mPGES-2 with GSH-heme bound. The ligands are drawn with black 
carbon atoms and the contacting residues with yellow carbon atoms. The color 
convention of figure 1c is used here. 
 
Figure 12. (a) Model of hGSTA3-3 as a complex with Δ5-androstene-3,17-dione 
(Δ5AD) and GSH, shown in stick form. The color convention from Figure 3 is used. 
(b) proposed mechanism of isomerization. 
 
Figure 13. (a) Isomerization of maleylacetoacetate (R = CH2COO-) and 
maleylpyruvate (R = COO-) to fumarylacetoacetate and fumarylpyruvate. Structure 
hGSTZ1-1 (b) and MPI (c) in the vicinity of the active-site. Ligands and surrounding 
residues are in stick form. All ligands are drawn with black carbon atoms. The color 
convention of figure 1 is used for the backbone cartoon. Residue R176 (c) occupies 
two discrete conformations. (d) The structure of dicarboxyethyl-GSH. (e) Proposed 
reaction mechanism of hGSTZ1-1 and MPI. 
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